Live Breaking News & Updates on Cns Pharmaceuticals Inc
Stay updated with breaking news from Cns pharmaceuticals inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
CNS Pharmaceuticals, Inc. (NASDAQ:CNSP – Get Rating) was the recipient of a significant decrease in short interest during the month of May. As of May 15th, there was short interest totalling 119,600 shares, a decrease of 44.6% from the April 30th total of 215,800 shares. Approximately 3.0% of the company’s stock are short sold. Based […] ....
CNS Pharmaceuticals, Inc. (NASDAQ:CNSP – Get Rating) saw a significant increase in short interest in the month of April. As of April 30th, there was short interest totalling 215,800 shares, an increase of 306.4% from the April 15th total of 53,100 shares. Based on an average daily volume of 3,210,000 shares, the days-to-cover ratio is […] ....
CNS Pharmaceuticals, Inc. (NASDAQ:CNSP – Get Rating) saw a significant growth in short interest in the month of April. As of April 15th, there was short interest totalling 53,100 shares, a growth of 410.6% from the March 31st total of 10,400 shares. Based on an average daily trading volume, of 3,000,000 shares, the short-interest ratio […] ....
CNS Pharmaceuticals, Inc. (NASDAQ:CNSP – Get Rating) saw a large growth in short interest during the month of April. As of April 15th, there was short interest totalling 53,100 shares, a growth of 410.6% from the March 31st total of 10,400 shares. Approximately 3.1% of the company’s shares are sold short. Based on an average […] ....
CNS Pharmaceuticals, Inc. (NASDAQ:CNSP – Get Rating) CEO John M. Climaco acquired 15,000 shares of the stock in a transaction dated Wednesday, April 12th. The stock was acquired at an average cost of $0.69 per share, with a total value of $10,350.00. Following the purchase, the chief executive officer now owns 45,010 shares of the […] ....